Pharma Focus Asia

Initial Dosing of Patient Commences in Clinical Study Investigating YOLT-101 for FH Therapy

Wednesday, April 03, 2024

YolTech Therapeutics has announced a significant milestone in its development of YOLT-101, an in vivo genome editing candidate for treating Familial Hypercholesterolemia (FH). The company has initiated an Investigator-Initiated Trial (IIT) by dosing the first patient with YOLT-101.

FH is a genetic disorder affecting the body's ability to remove low-density lipoprotein (LDL) cholesterol from the bloodstream, leading to an increased risk of early heart disease.

YOLT-101, developed independently by YolTech, targets specific genetic mutations associated with FH using advanced gene editing technology and lipid nanoparticle (LNP) delivery. Preclinical studies in non-human primate (NHP) models have shown significant and sustained reduction in LDL-C levels for nearly two years after a single dose.

The clinical trial initiated by investigators is a single-arm, open-label, dose-escalation study. Its primary objectives include assessing the safety and tolerability of YOLT-101, determining the Optimal Biologically Active Dose (OBD), and preliminarily evaluating its impact on lipid and lipoprotein levels in FH patients.

Dr. Yuxuan Wu, Founder and CEO of YolTech, expressed optimism about the potential of YOLT-101 to revolutionize treatment for FH patients. YolTech is committed to advancing the clinical development of YOLT-101 and collaborating closely with regulatory authorities, healthcare professionals, and patient advocacy groups.

YOLT-101 is an in vivo liver-based editing therapy designed to permanently deactivate the PCSK9 gene, thereby reducing disease-driving LDL-C levels. It is currently undergoing evaluation in the IIT clinical trial for patients with high-risk heterozygous FH, established atherosclerotic cardiovascular disease (ASCVD), and uncontrolled LDL-C levels on standard-of-care therapy.

 

Source: prnewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024